OncoMatch

OncoMatch/Gastric / Stomach Cancer/HER2 (ERBB2)

Gastric / Stomach CancerHER2 (ERBB2) Clinical Trials

41 recruiting trials·Updated daily from ClinicalTrials.gov

HER2 overexpression or amplification (IHC 3+ or IHC 2+/FISH+) occurs in approximately 20% of gastric and gastroesophageal junction adenocarcinomas and is the strongest predictive biomarker in this disease. Trastuzumab added to platinum/fluoropyrimidine chemotherapy is the first-line standard for HER2-positive advanced gastric cancer; trastuzumab deruxtecan (T-DXd) is approved in the second-line setting. Trials investigate T-DXd combinations, bispecific HER2 antibodies, and novel ADCs across HER2 expression levels.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting HER2 (ERBB2) Gastric / Stomach Cancer trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 329 US sites

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Shanghai Henlius Biotech

Phase 318 US sites

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Daiichi Sankyo

Phase 2/Phase 3

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

RemeGen Co., Ltd.

Phase 2/Phase 3

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Shanghai JMT-Bio Inc.

Phase 2/Phase 3

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

SUNHO（China）BioPharmaceutical CO., Ltd.

Phase 3

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

RemeGen Co., Ltd.

Additional trials

More HER2 (ERBB2) Gastric / Stomach Cancer trials

See all in search →
Phase 2
NCT06157892A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsPhase 281 US sitesNCT06324357Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPhase 1/Phase 225 US sitesNCT05702229Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaPhase 211 US sitesNCT04379596Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Phase 210 US sitesNCT06123338A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric CancerPhase 210 US sitesNCT07069712A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaPhase 27 US sitesNCT06921928Study for AZD4360 in Participants With Advanced Solid TumoursPhase 1/Phase 23 US sitesNCT07070466Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAPhase 22 US sitesNCT03526835A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPhase 1/Phase 223 US sites
15 international trials (no US sites)
NCT06793917Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaPhase 3NCT06560528Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 OverexpressionPhase 2NCT07334431Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric CancerPhase 1/Phase 2NCT06487429Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric CancerPhase 2NCT07194005Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric CancerPhase 2NCT06730373First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)Phase 2NCT06253650Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual DiseasePhase 2NCT05975749Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric CancerPhase 2NCT07025889IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric CancerPhase 1/Phase 2NCT06253611First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric CancerPhase 2NCT05771584Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric CancerPhase 2NCT06155383Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.Phase 2NCT06630130Perioperative Therapies in Locally Advanced Unresectable Gastric CancerPhase 2NCT06121700Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerPhase 2NCT07176312Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PatientsPhase 2
Related therapies

FDA-approved therapies for HER2 (ERBB2) Gastric / Stomach Cancer

Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.

Trastuzumab DeruxtecanHER2-directed antibody-drug conjugateHER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma
Other Gastric / Stomach Cancer biomarkers

Browse other molecular targets with active Gastric / Stomach Cancer trials.

PD-L1 (CD274)FGFR2MMR / MSI-H
← All Gastric / Stomach Cancer clinical trials